argenx Presents New Efgartigimod Data Showing Long-Term Sustained Patient Benefit in Myositis ...

Belgian biotech argenx just delivered compelling long-term data for its blockbuster efgartigimod (Vyvgart) in two severe autoimmune conditions, myositis and Sjogren's disease, significantly broadening the therapeutic potential of its flagship FcRn inhibitor. New ALKIVIA+ and RHO+ trial results, unveiled ahead of an anticipated major rheumatology conference, demonstrate sustained clinical improvements and a consistent safety profile, particularly highlighting the convenience of biweekly dosing for Sjogren's patients. This positions efgartigimod to capture a larger share of the lucrative autoimmune market. The data solidifies argenx strategy to become a multi-disease powerhouse, leveraging efgartigimod mechanism of reducing pathogenic IgG antibodies across a spectrum of autoimmune disorders. With competitors like UCB and Roche also vying for dominance in this space, these positive results are crucial. The sustained benefits observed, up to 99 weeks in myositis and 52 weeks in Sjogren's, not only promise better patient outcomes but also provide a strong narrative for regulatory discussions and market adoption, especially as current treatments often come with significant side effects or limited efficacy. Following these robust readouts, expect argenx to accelerate regulatory filings for efgartigimod in both indications, likely targeting submissions in late 2026 or early 2027. The cross-indication safety analysis further strengthens their case, suggesting a predictable and favorable risk-benefit profile that could pave the way for an even wider label expansion into other IgG-mediated diseases. Investors will be closely watching for initial sales projections for these new indications and any further pipeline updates that capitalize on the drug's versatile platform.